News
Novo Nordisk, Freeze
Digest more
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...
Novo Nordisk Inc. secured a court order trimming litigation over its 401(k) plan, when a New Jersey federal judge dismissed ...
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
Trying to work out what to do with Novo Nordisk stock right now? You are not alone. Investors everywhere are weighing up whether to jump in, sit tight, or walk away as the market continues to shift.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback